SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Faivre-Finn C, West C, Lorigan P, et al. Thoracic radiation radiotherapy for limited-stage small-cell lung cancer: controversies and future developments. Clin Oncol (R Coll Radiol). 2005; 17: 591-598.
  • 2
    Pignon JP, Arriagada R, Idhe D, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992; 327: 1618-1622.
  • 3
    Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell lung cancer. A meta-analysis. J Clin Oncol. 1992; 10: 890-895.
  • 4
    Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999; 341: 476-484.
  • 5
    Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002; 20: 4665-4672.
  • 6
    Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999; 340: 265-271.
  • 7
    Schild SE, Bonner JA, Hillman S, et al. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). J Clin Oncol. 2007; 25: 3124-3129.
  • 8
    Baas P, Belderbos JS, Senan S, et al. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. Br J Cancer. 2006; 94: 625-;630.
  • 9
    Spiro SG, James LE, Rudd RM, et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol. 2006; 24: 3823-3830.
  • 10
    Chen GY, Jiang GL, Wang LJ, et al. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial. Int J Radiat Oncol Biol Phys. 2005; 61: 70-75.
  • 11
    Bogart JA, Herndon JE 2nd, Lyss AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004; 59: 460-468.
  • 12
    Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002; 20: 3054-3060.
  • 13
    Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001; 12: 1231-1238.
  • 14
    Jeremic B, Shibamoto Y, Acimovic L, et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol. 1997; 15: 893-900.
  • 15
    Videtic GM, Belderbos JS, Spring Kong FM, et al. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: small-cell lung cancer (SCLC). Int J Radiat Oncol Biol Phys. 2008; 72: 327-334.
  • 16
    Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep (part 3). 1973; 4: 31-42.
  • 17
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31: 1341-1346.
  • 18
    Socinski MA, Bogart JA. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol. 2007; 25: 4137-4145.
  • 19
    Kies MS, Mira JG, Crowley JJ, et al. Multimodal therapy for limited small-cell lung cancer. A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group study. J Clin Oncol. 1987; 5: 592-600.
  • 20
    De Ruysscher D, Bremer RH, Koppe F, et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol. 2006; 80: 307-312.
  • 21
    Perez CA, Krauss S, Bartolucci AA, et al. Thoracic and elective brain irradiation with concomitant or delayed multiagent chemotherapy in the treatment of localized small cell carcinoma of the lung: a randomized prospective study by the Southeastern Cancer Study Group. Cancer. 1981; 47: 2407-2413.
  • 22
    White JE, Chen R, McCracken J, et al. The influence of radiation therapy quality control on survival, response and sites of relapse in oat cell carcinoma of the lung: preliminary report of a Southwest Oncology Group study. Cancer. 1982; 50: 1084-1090.
  • 23
    Liengswangwong V, Bonner JA, Shaw EG, et al. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and implications for thoracic radiotherapy. J Clin Oncol. 1994; 12: 496-502.
  • 24
    Brodin O, Rikner G, Steinholz L, et al. Local failure in patients treated with radiotherapy and multidrug chemotherapy for small cell lung cancer. Acta Oncol. 1990; 29: 739-746.
  • 25
    Azad A, Chionh F, Scott AM, et al. High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol. 2010; 12: 443-451.
  • 26
    van Loon J, Offermann C, Bosmans G, et al. 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. Radiother Oncol. 2008; 87: 49-54.
  • 27
    Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007; 18: 338-345.
  • 28
    Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol. 2004; 22: 3248-3254.
  • 29
    Kamel EM, Zwahlen D, Wyss MT, et al. Whole-body F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med. 2003; 44: 1911-1917.
  • 30
    Vinjamuri M, Craig M, Campbell-Fontaine A, et al. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer. 2008; 9: 30-34.
  • 31
    van Loon J, De Ruysscher D, Wanders R, et al. Selective nodal irradiation on basis of FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2010; 77: 329-336.
  • 32
    van Overhagen H, Brakel K, Heijenbrok MW, et al. Metastases in supraclavicular lymph nodes in lung cancer: assessment with palpation, US, and CT. Radiology. 2004; 232: 75-80.
  • 33
    Zhao L, Chen M, Ten Haken R, et al. Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiother Oncol. 2007; 82: 153-159.
  • 34
    Chen M, Hayman JA, Ten Haken RK, Tatro D, Fernando S, Kong FM. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation? Int J Radiat Oncol Biol Phys. 2006; 64: 120-126.
  • 35
    Rosenzweig KE, Sim SE, Mychalczak B, Braban LE, Schindelheim R, Leibel SA. Elective nodal irradiation in the treatment of non-small-cell lung cancer with 3-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2001; 50: 681-685.
  • 36
    Komaki R, Swann RS, Ettinger DS, et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys. 2005; 62: 342-350.
  • 37
    Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide. http://www.clinicaltrials.gov/ct2/show/NCT00632853. Accessed January 1, 2010.
  • 38
    Cisplatin, Etoposide, and Two Different Schedules of Radiation Therapy in Treating Patients With Limited Stage Small Cell Lung Cancer. http://www.clinicaltrials.gov/ct2/show/NCT00433563. Accessed January 1, 2010.
  • 39
    Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004; 22: 4837-4845.
  • 40
    De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol. 2006; 24: 1057-1063.